Spike Glycoprotein, Coronavirus
"Spike Glycoprotein, Coronavirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion.
Descriptor ID |
D064370
|
MeSH Number(s) |
D12.776.543.512.500.665 D12.776.964.970.880.910.665
|
Concept/Terms |
Spike Glycoprotein, Coronavirus- Spike Glycoprotein, Coronavirus
- Coronavirus Spike Glycoprotein
- Spike Protein, Coronavirus
- Coronavirus Spike Protein
- Glycoprotein S, Coronavirus
- Spike Glycoproteins, Coronavirus
|
Below are MeSH descriptors whose meaning is more general than "Spike Glycoprotein, Coronavirus".
Below are MeSH descriptors whose meaning is more specific than "Spike Glycoprotein, Coronavirus".
This graph shows the total number of publications written about "Spike Glycoprotein, Coronavirus" by people in this website by year, and whether "Spike Glycoprotein, Coronavirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2020 | 8 | 7 | 15 |
2021 | 18 | 10 | 28 |
2022 | 1 | 23 | 24 |
2023 | 1 | 7 | 8 |
2024 | 9 | 7 | 16 |
2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Spike Glycoprotein, Coronavirus" by people in Profiles.
-
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
-
Placentas From SARS-CoV-2 Infection During Pregnancy Exhibit Foci of Oxidative Stress and DNA Damage. Am J Reprod Immunol. 2025 Jan; 93(1):e70034.
-
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
-
Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV. J Clin Invest. 2024 Nov 26; 135(3).
-
Revealing patterns of SARS-CoV-2 variant emergence and evolution using RBD amplicon sequencing of wastewater. J Infect. 2024 Nov; 89(5):106284.
-
Discovery and characterization of a pan-betacoronavirus S2-binding antibody. Structure. 2024 Nov 07; 32(11):1893-1909.e11.
-
Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins. Viruses. 2024 Sep 20; 16(9).
-
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages. Emerg Microbes Infect. 2024 Dec; 13(1):2402880.
-
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Nat Commun. 2024 Sep 11; 15(1):7954.
-
Convergence of SARS-CoV-2 spike antibody levels to a population immune setpoint. EBioMedicine. 2024 Oct; 108:105319.